Clinical trials: DME
Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)
ABBV-RGX-314 is being developed as a novel, potential one-time gene therapy treatment for the treatment of Diabetic Retinopathy (DR) with and without Center-Involved Diabetic Macular Edema (CI-DME).
- Trial name
- ALTITUDE® (NCT04567550)
- Testing
- ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3
- Where
- 25 sites in United States
- Volunteers
- 139 people
- Sponsor
- AbbVie
nAMD, DME
Real-World Study of Intravitreal Aflibercept 8 mg in Pretreated Eyes With nAMD or DME
The goal of this multicentre observational study is to evaluate the interval-extension potential, effectiveness, and safety of intravitreal aflibercept 8 mg in pretreated eyes with neovascular age-related macular degeneration…
- Trial name
- ALLEVI8 (NCT07761039)
- Testing
- Aflibercept 8mg
- Volunteers
- 100 people
- Sponsor
- Grupo de Estudos da Retina
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME)
Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
This study is a prospective, non-interventional, multicenter, open-label study in nAMD and DME patients being treated with brolucizumab according to the EU SmPC.
- Trial name
- BLUE SKY (NCT04543331)
- Testing
- brolucizumab
- Where
- 41 sites in Germany
- Volunteers
- 572 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy, Diabetic Macular Edema (DME)
AI Prediction of Treatment Response in DME
Diabetic macular edema (DME) is a leading cause of vision loss among individuals with diabetes mellitus. Although intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is the standard treatment for…
- Trial name
- NCT07707856
- Testing
- Artificial Intelligence-Based Imaging Analysis
- Where
- Egypt
- Volunteers
- 1,284 people
- Sponsor
- Benha University
Visual Impairment, Neovascular Age-related Macular Degeneration (nAMD)
The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema
This is an observational study in which only data are collected from people who have already been prescribed aflibercept 8 mg by their own doctors.
- Conditions
- Visual Impairment, Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macula Edema (DME)
- Trial name
- NCT06075147
- Testing
- Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
- Where
- 18 sites in Australia, Canada and 16 more
- Volunteers
- 2,500 people
- Sponsor
- Bayer
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.
The main goal of this study is to find out how common certain eye diseases are in Germany and how they have changed over time. The diseases being studied are: nAMD (neovascular age-related macular degeneration): a condition that…
- Trial name
- NCT07308639
- Testing
- anti-VEGF medication
- Where
- Germany
- Volunteers
- 50,000 people
- Sponsor
- Bayer
Diabetic Macular Edema (DME)
Zhuochuming®-3T&E-DME Study (Treatment-naïve Patients)
The goal of this clinical trial is to understand whether Zhuochuming® (Aflibercept Intravitreal Injection) using a 3 loading doses followed by a treat-and-extend regimen (3+T\&E) can treat patients with diabetic macular edema…
- Trial name
- NCT07612904
- Testing
- Aflibercept Intravitreous Injection
- Where
- China
- Volunteers
- 186 people
- Sponsor
- The Third Peoples Hospital of Dalian
Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)
Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
Regeneron Pharmaceuticals developed a single-dose pre-filled syringe (PFS) to deliver 8 mg aflibercept. The PFS is a convenient device that contains the study medication that will be injected in your study eye.
- Trial name
- NCT05989126
- Testing
- aflibercept 8 mg PFS
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Regeneron Pharmaceuticals
DME, Retinal Vein Occlusion (RVO)
AI vs. Physician for Anti-VEGF Decision-Making: An RCT
We developed an artificial intelligence system, called QiLin, which was designed to assist anti-VEGF treatment decisions in retinal diseases.
- Conditions
- DME, Retinal Vein Occlusion (RVO), Neovascular (Wet) Age-Related Macular Degeneration
- Trial name
- NCT07328776
- Testing
- QiLin-assisted, physician only, without QiLin assisted
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME)
A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema
This is an observational study in which data already collected from participants with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) is studied.
- Trial name
- NCT06929143
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- Japan
- Volunteers
- 3,000 people
- Sponsor
- Bayer
Diabetic Macular Edema (DME)
A Study of Avoralstat In Participants With Diabetic Macular Edema
The goal of this study is to assess the safety and therapeutic potential of a single dose of avoralstat in adult participants with DME.
- Trial name
- NCT07228559
- Testing
- avoralstat
- Where
- 8 sites in United States, Australia
- Volunteers
- 3 people
- Sponsor
- BioCryst Pharmaceuticals
Diabetic Retinopathy (DR), Diabetic Macular Edema (DME)
Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizumab
The goal of this clinical trial is to see if treatment with faricimab or biosimilar ranibizumab leads to different early imaging changes in adults with diabetic retinopathy requiring anti-VEGF treatment and to identify OCT and…
- Trial name
- NCT07520045
- Testing
- Faricimab, Biosimilar ranibizumab
- Where
- Croatia
- Volunteers
- 100 people
- Sponsor
- Osijek University Hospital
Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD)
Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections
This Phase 4, multicenter, randomized, double-masked clinical study evaluates the efficacy and safety of chloroprocaine hydrochloride ophthalmic gel 3% (IHEEZO) compared with routine anesthesia (topical proparacaine 0.5% combined…
- Conditions
- Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion, Diabetic Retinopathy (DR)
- Trial name
- Quell (NCT07456826)
- Testing
- Chloroprocaine Ophthalmic Gel 3% (IHEEZO), Proparacaine Hydrochloride Ophthalmic Solution 0.5%, Lidocaine Hydrochloride Injection 2%
- Where
- United States
- Volunteers
- 236 people
- Sponsor
- Harrow Inc
Age Related Macular Degeneration (ARMD), Retinal Vein Occlusion (RVO)
Comparison of Intravitreal Anti-VEGF Treatment Burden in Different Retinal Diseases
The study compares the perceived treatment burden in patients undergoing intravitreal anti-VEGF treatment for either wet age related macular degeneration, macular edema after retinal vein occlusions or diabetic macular edema.
- Conditions
- Age Related Macular Degeneration (ARMD), Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME)
- Trial name
- NCT07514559
- Where
- Austria
- Volunteers
- 393 people
- Sponsor
- Hospital Hietzing
Diabetic Macular Edema (DME)
Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema
A multicenter, randomized, double-blind, parallel-group, active-controlled non-inferiority trial. A total of 406 subjects with diabetic macular edema (DME) were planned for enrollment.
- Trial name
- NCT07515079
- Testing
- BAT5906 injection, Lucentis
- Where
- 50 sites in China
- Volunteers
- 406 people
- Sponsor
- Bio-Thera Solutions
Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324
- Trial name
- JADE (NCT07484074)
- Testing
- Faricimab, OLN324
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 164 people
- Sponsor
- Ollin Biosciences, Inc.
Diabetic Macular Edema (DME)
Safety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients
The goal of this study is to evaluate the safety and efficacy of LX111 treatment of DME. This study will enroll participants aged ≥ 18 vears old to receive a single unilateral intravitreal (lVT) injection of LX111 to evaluate its…
- Trial name
- NCT07362927
- Testing
- LX111 Injection
- Where
- 2 sites in China
- Volunteers
- 32 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Diabetic Macular Edema (DME)
Efficacy Comparison of DExamethasone Intravitreal Implant Combined With Aflibercept Versus Aflibercept Monotherapy in Treatment-naïve Inflammatory Diabetic Macular Edema Patients
This is a 12-month, prospective, randomized controlled, multi-center, open-label, superiority designed study. Treatment-Naïve DME patient with inflammatory biomarkers, who meet the inclusion and exclusion criteria, will be…
- Trial name
- DECADE (NCT07438119)
- Testing
- Combination Therapy with Aflibercept Intravitreous Injection (2mg) and Dexamethasone Intravitreal Implant, Aflibercept Intravitreous Injection (2mg) Monotherapy
- Volunteers
- 114 people
- Sponsor
- Kun Liu
Diabetic Macular Edema (DME)
Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema
Diabetic macular edema is a frequent complication of long-standing diabetes mellitus in which fluid leaks into the central part of the retina (macula), leading to reduced vision.
- Trial name
- NCT07338097
- Testing
- Aflibercept (2.0 mg), Bevacizumab
- Where
- Pakistan
- Volunteers
- 116 people
- Sponsor
- CMH Multan Institute of Medical Sciences
Diabetic Retinopathy (DR), Diabetic Macular Edema (DME)
Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract Surgery
Objective of this randomised controlled trial is to compare the efficacy of a single per operative anti VEGF injection with repeated postoperative anti VEGF injections in the prevention of diabetic retinopathy progression after…
- Conditions
- Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Cataract, Phacoemulfisication+IOL Implantation
- Trial name
- NCT07301775
- Testing
- Aflibercept (Eylea)
- Where
- 2 sites in Pakistan
- Volunteers
- 166 people
- Sponsor
- Ahmad Zeeshan Jamil